Dr. Daniel Dejesus Escalante is a Parker, Colorado based Oral and Maxillofacial Surgeon who is specialized in Oral and Maxillofacial Surgery. He may accept the Medicare-approved amount. Patients may be billed for more than the Medicare deductible and coinsurance. His current practice location is 19700 E Parker Square Dr, Parker. Patients can reach him at 303-840-2300.
Dr. Daniel Dejesus Escalante deals with the diagnosis, surgical and adjunctive treatment of diseases, injuries and defects involving both the functional and esthetic aspects of the hard and soft tissues of the oral and maxillofacial region.
Complete Profile:
Dr. Daniel Dejesus Escalante speciality, credentials, practice address, contact phone number and fax are as below.
Patients can directly walk in or can call on the below given phone number for appointment.
Name:
Dr. Daniel Dejesus Escalante
Specialization:
Oral and Maxillofacial Surgeon
Gender:
Male
Credentials:
DMD
Accepts Medicare Assignment:
May Accept
Practice Address:
19700 E Parker Square Dr, Parker, Colorado, 80134-7301
Phone:
303-840-2300
Fax:
702-995-4193
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details are as mentioned below.
PAC ID:
7214228899
Enrollment ID:
I20160629001532
NPI Number:
1245203041
NPI Enumeration Date:
10 Feb, 2006
NPI Last Update On:
05 Jan, 2018
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
8148 S Wabash Ct, Centennial, Colorado
Zip:
80112-3329
Phone Number:
617-504-0420
Fax Number:
702-995-4193
Patients can reach Dr. Daniel Dejesus Escalante at 19700 E Parker Square Dr, Parker, Colorado or can call to book an appointment on 303-840-2300. Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 November, 2024.